Tempest Therapeutics (NASDAQ: TPST) seeks shareholder vote to amend charter
Rhea-AI Filing Summary
Tempest Therapeutics is asking shareholders to approve an amendment to its certificate of incorporation that would replace specified supermajority voting requirements with majority-of-outstanding standards and permit stockholder action by written consent. The Board unanimously recommends approval. The proposal requires the affirmative vote of holders of at least 75% of voting power to pass under the Existing CoI and, if approved, the Company would file a Certificate of Amendment with the Delaware Secretary of State and make conforming bylaw changes. The record date for the Special Meeting is May 28, 2026, the meeting is virtual on July 27, 2026, and holders of 14,806,997 shares were outstanding on the Record Date.
Positive
- None.
Negative
- None.
Insights
Proposal seeks to modernize voting thresholds and allow written consents.
The proposed Certificate of Amendment replaces certain supermajority provisions with a majority-of-outstanding voting standard and expressly permits stockholder action by written consent, subject to the majority-of-outstanding vote described in the amendment. The Board has unanimously recommended the change.
Key dependencies include the required affirmative vote and the Board’s retained ability to abandon the amendments even if approved; timing is tied to filing the Certificate of Amendment after shareholder approval.
The amendment alters charter mechanics for bylaws, special meetings, and written consents.
The draft replaces Article provisions to: (1) permit stockholder written consents requiring majority-of-outstanding voting power; (2) require majority-of-outstanding votes to adopt/amend bylaws; and (3) restrict calling special meetings to the Board or CEO only. These are charter-level governance changes under Section 242 of the DGCL.
Practical effects depend on filing the Certificate of Amendment; the amendment also includes an express reservation allowing the Board to abandon the amendments despite shareholder approval.


